RxDoctor Payments Data

Lyndee Miller

Saint George, UTNPI 1720720253

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations.

$1,434in general payments, 2019–2025

Across 78 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$260
  • Pfizer$154
  • Novartis$127
  • Novo Nordisk$108
  • Lundbeck LLC$92
  • Amgen$86
  • plus $606 from 18 others

What the payments were for

  • Food & beverage$1,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate11$85
Azithromycin16$47

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →